New Study for Alzheimer’s
A new placebo-controlled study in 410 patients suffering from mild to moderate Alzheimer’s disease or vascular dementia has demonstrated the efficacy of EGb 761. Like the majority of dementia patients encountered in everyday clinical practice, the patients in the study suffered from both cognitive impairment and neuropsychiatric symptoms such as depressed mood, anxiety, irritability or aggression. During the observation period of 24 weeks, EGb 761 improved both cognitive functioning and neuropsychiatric symptoms of the patients significantly.